Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257163 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
A Phase 2 study of Gastric Adenocarcinoma and Stage III Gastric Cancer AJCC v7, sponsored by Rutgers, The State University of New Jersey.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT03257163 is a Phase 2 study of Gastric Adenocarcinoma and Stage III Gastric Cancer AJCC v7 that is active but no longer recruiting, run by Rutgers, The State University of New Jersey. The registered enrollment target is 40 participants, below the 244-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (84% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT03257163, a Phase 2 study of Gastric Adenocarcinoma and Stage III Gastric Cancer AJCC v7, is active but no longer recruiting, sponsored by Rutgers, The State University of New Jersey.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial studies how well pembrolizumab works with capecitabine and radiation therapy in treating patients with mismatch repair deficient and Epstein-Barr virus positive gastric cancer. Monoclonal antibodies, such as pembrolizumab may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab, capecitabine and radiation therapy may work better at treating gastric cancer.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Capecitabine
- OTHER Laboratory Biomarker Analysis
- RADIATION Radiation Therapy
Study Locations (4)
New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton - Hamilton
- Rutgers Cancer Institute of New Jersey - New Brunswick
Georgia
- Emory University - Atlanta
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03257163
The ClinicalTrials.gov registry entry for NCT03257163 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 244-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (84% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03257163 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New Jersey, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT03257163 about?
NCT03257163 is a clinical study titled "Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer". This phase II trial studies how well pembrolizumab works with capecitabine and radiation therapy in treating patients with mismatch repair deficient and Epstein-Barr virus positive gastric cancer. Monoclonal antibodies, such as pembrolizumab may interfere with the ability of tumor cells to grow and ...
What is the current status of trial NCT03257163?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2017-09-29. Estimated completion is 2026-12-31.
What conditions does trial NCT03257163 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Stage III Gastric Cancer AJCC v7, Epstein-Barr Virus Positive, Mismatch Repair Protein Deficiency, Stage IB Gastric Cancer AJCC v7.
What interventions are being tested in trial NCT03257163?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Capecitabine (DRUG), Laboratory Biomarker Analysis (OTHER), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03257163?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03257163 being conducted?
This trial has 4 study locations across Georgia, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
-
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
RECRUITING · Phase 2
-
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RECRUITING · Phase 2
-
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.